Article Chemotherapy Compounding Pharmacies 
Pharmacy Times
JULY 16, 2025
The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 Pharmacy Times. months; HR, 0.60; 95% CI, 0.47-0.77); 0.77); this now presents a new standard of care for these patients. June 5, 2025. Accessed June 23, 2025.
Pharmacy Times
JUNE 9, 2025
SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. 1,2 Nivolumab and chemotherapy is a standard of care option for resectable non-small cell lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. Acalabrutinib plus bendamustine and rituximab may become new standard care for untreated MCL.
Pharmacy Times
AUGUST 8, 2025
2 In patients who had received prior platinum-based chemotherapy but had not been treated with a HER2-targeted TKI or antibody-drug conjugate (ADC; n = 71), the ORR was approximately 75% (95% CI, 63–83), with 58% of patients achieving a DOR of at least 6 months.
Pharmacy Times
JUNE 9, 2025
doi:10.1056/NEJMoa1901963 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. N Engl J Med. 2019;380:2020-2030. Subscribe Now!
Pharmacy Times
JUNE 18, 2025
Implementation and evaluation of social determinants of health practice models within community pharmacy. Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. J Am Pharm Assoc (2003). 2022;62(4):1407-1416.doi:10.1016/j.japh.2022.02.005
Pharmacy Times
JUNE 11, 2025
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Expert insights. Personalized for you.
Let's personalize your content